Abstract
Currently, the emergence of a novel human corona virus, SARS-CoV-2, has become a global health concern causing severe respiratory tract infections in humans. Human-to-human transmissions have been described with incubation times between 2-14 days, facilitating its spread via droplets, contaminated hands or surfaces, resulting in high spread and death rates according to date, time and place of infection. We therefore reviewed the literature on all available information about the treatment of the cases, especially critical cases to decrease the mortality rate, the spread and incubation time of the virus by using the adaptive artificial passive immunity (anti-bodies from fully recovered patients with COVID-19).
Highlights
A novel corona virus (SARS-CoV-2) has recently developed from China with a total of 82,930 or more confirmed cases of pneumonia with 3341 total death cases [1]
It is an obligatory issue to prevent any further spread of the virus in the public and healthcare places
When coming into contact with a non-self body, T cells turn into so-called T effector cells, which trigger and regulate different defense reactions
Summary
A novel corona virus (SARS-CoV-2) has recently developed from China with a total of 82,930 or more confirmed cases of pneumonia with 3341 total death cases (as of April 5, 2020) [1]. Transmission of corona viruses from contaminated dry surfaces has been suggested including self-inoculation of mucous membranes of the nose, eyes or mouth [4,5]. The aim of this short communication was to treat the critical cases and decrease the spread and incubation period of the virus, by transferring the antibodies of fully recovered patients to other ones with some precautions
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
